Stocks and Investing
Stocks and Investing
Thu, May 2, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Kaplan Maintained (TGTX) at Strong Buy with Increased Target to $40 on, May 2nd, 2024
Matthew Kaplan of Ladenburg Thalmann, Maintained "TG Therapeutics, Inc." (TGTX) at Strong Buy with Increased Target from $39 to $40 on, May 2nd, 2024.
Matthew has made no other calls on TGTX in the last 4 months.
There are 3 other peers that have a rating on TGTX. Out of the 3 peers that are also analyzing TGTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $13 on, Thursday, February 29th, 2024
These are the ratings of the 2 analyists that currently disagree with Matthew
- Eric Joseph of "JP Morgan" Reiterated at Buy and Held Target at $25 on, Thursday, April 18th, 2024
- Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $29 on, Monday, February 5th, 2024
Contributing Sources